Brief: Biomarin Pharmaceutical Expects Q3 Will Include Acquired Ipr&D Charges Of About $221 Million
07/10/2025 22:55
Oct 7 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O: BIOMARIN PHARMACEUTICAL INC: EXPECTS Q3 WILL INCLUDE ACQUIRED IPR&D CHARGES OF APPROXIMATELY $221 MILLION ON A PRE-TAX BASIS DUE TO INOZYME PHARMA DEAL BIOMARIN PHARMACEUTICAL INC - FOR Q3, CO EXPECTS CHARGE OF ABOUT $1.10 TO BOTH GAAP AND NON-GAAP EPS DUE TO INOZYME PHARMA DEAL Further company coverage: BMRN.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife